Shanghai Medicilon (SHSE:688202) ROE % Adjusted to Book Value : -4.76% (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Shanghai Medicilon ROE % Adjusted to Book Value?

Shanghai Medicilon's ROE % for the quarter that ended in Sep. 2024 was -9.81%. Shanghai Medicilon's PB Ratio for the quarter that ended in Sep. 2024 was 2.06. Shanghai Medicilon's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -4.76%.

Shanghai Medicilon ROE % Adjusted to Book Value Historical Data

The historical data trend for Shanghai Medicilon's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Medicilon ROE % Adjusted to Book Value Chart

Shanghai Medicilon Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

2.73

1.41

1.01

1.99

-0.44

Shanghai Medicilon Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-2.43	-6.23	-2.67	-3.70	-4.76

Competitive Comparison of Shanghai Medicilon's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Shanghai Medicilon's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Medicilon's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Medicilon's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Shanghai Medicilon's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Shanghai Medicilon ROE % Adjusted to Book Value Calculation

Shanghai Medicilon's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-1.61%	/	3.67
	=	-0.44%

Shanghai Medicilon's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-9.81%	/	2.06
	=	-4.76%

Shanghai Medicilon ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Shanghai Medicilon's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Medicilon Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Medicilon Inc (SHSE:688202) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lane 67, Libing Road, Building 5, Pilot Free Trade Zone, Shanghai, CHN, 201299

Website

http://www.medicilon.com.cn

Shanghai Medicilon Inc is a comprehensive biomedical research and developemnt service company. It provides a full range of one-stop new drug development services for pharmaceutical companies and research institutions around the world in line with domestic and international reporting standards.

Executives

Chen Jin Zhang	Director
Chen Guo Xing	Director
Lin Zhang Qing	Director
Peng Shuang Qing	Core technical personnel
Li Zhi Gang	Core technical personnel
Xu Yong Mei	Core technical personnel
Liu Bin Bin	senior management
Zhang Xiao Dong	senior management
Xue Chao	senior management
Ma Xing Quan	senior management
	Directors, senior managers, core technical personn
Cai Jin Na	Directors, senior managers

Shanghai Medicilon Headlines

No Headlines